Skip to main content

FATE

Stock
Health Care
Biotechnology

Performance overview

FATE Price
Price Chart

Forward-looking statistics

Beta
2.32
Risk
96.75%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

Company info

SectorHealth Care
IndustryBiotechnology
Employees331
Market cap$418.9M

Fundamentals

Enterprise value-$28.7M
Revenue$13.3M
Revenue per employee—
Profit margin0.00%
Debt to equity28.89

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$1.49
Dividend per share—
Revenue per share$0.11
Avg trading volume (30 day)$2M
Avg trading volume (10 day)$2M
Put-call ratio—

Macro factor sensitivity

Growth+6.9
Credit+5.2
Liquidity-2.0
Inflation+1.4
Commodities+1.5
Interest Rates-2.4

Valuation

Dividend yield0.00%
PEG Ratio-0.67
Price to sales9.63
P/E Ratio-0.67
Enterprise Value to Revenue-2.15
Price to book0.44

Upcoming events

Next earnings dayAugust 11, 2025
Next dividend day—
Ex. dividend day—

News

Why Is Fate Therapeutics (FATE) Up 61.5% Since Last Earnings Report?

Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research (June 12, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free